Climb Bio (NASDAQ:CLYM) Upgraded by Leerink Partnrs to “Strong-Buy” Rating

Leerink Partnrs upgraded shares of Climb Bio (NASDAQ:CLYM) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Climb Bio’s Q4 2024 earnings at ($0.15) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS, FY2027 earnings at ($1.12) EPS and FY2028 earnings at ($1.74) EPS.

Separately, Leerink Partners began coverage on Climb Bio in a report on Monday. They issued an “outperform” rating and a $10.00 target price on the stock.

Climb Bio Stock Performance

Climb Bio stock traded down $0.03 during trading on Monday, reaching $3.23. The company had a trading volume of 9,111 shares, compared to its average volume of 454,135. The company has a market cap of $217.12 million, a price-to-earnings ratio of -1.53 and a beta of -0.40. Climb Bio has a 12-month low of $2.35 and a 12-month high of $11.55.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.